Antibiotic cross-resistance in the lab and resistance co-occurrence in the clinic: Discrepancies and implications in E. coli

Infection, Genetics and Evolution

Volumn 40, Issue , 2016, Pages 155-161

  Obolski, Uri ^a   Dellus Gur, Eynat ^a   Stein, Gideon Y ^b   Hadany, Lilach ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

Antibiotic resistance; Cross resistance; E. coli; Mathematical model; Multi drug resistance

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFALOTIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; OFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIMENTIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; BAYES THEOREM; BLOOD CULTURE; COMPARATIVE STUDY; CROSS RESISTANCE; DRUG SENSITIZATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; HOSPITAL; HUMAN; ISRAEL; LABORATORY; MATHEMATICAL MODEL; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; ALGORITHM; CROSS INFECTION; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; ODDS RATIO; THEORETICAL MODEL;

ALGORITHMS; ANTI-BACTERIAL AGENTS; BAYES THEOREM; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, THEORETICAL; ODDS RATIO;

EID: 84960084941     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2016.02.017     Document Type: Article

References (34)

1. Aloush V., Navon-Venezia S., Seigman-Igra Y., Cabili S., Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob. Agents Chemother. 2006, 50:43-48.
2. Barlow M. What antimicrobial resistance has taught us about horizontal gene transfer, horizontal gene transfer. 2009, 397-ssss. Springer.
3. Bonhoeffer S., Lipsitch M., Levin B.R. Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl. Acad. Sci. 1997, 94:12106-12111.
4. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., Scheld M., Spellberg B., Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America. Clin. Infect. Dis. 2009, 48:1-12.
5. Brusselaers N., Vogelaers D., Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann. Intensive Care 2011, 1:1-7.
6. Courvalin P. Transfer of antibiotic resistance genes between gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. 1994, 38:1447.
7. Davies J., Davies D. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 2010, 74:417-433.
8. Dzidic S., Bedeković V. Horizontal gene transfer-emerging multidrug resistance in hospital bacteria. Acta Pharmacol. Sin. 2003, 24:519-526.
9. Fuentes-Hernandez A., Plucain J., Gori F., Pena-Miller R., Reding C., Jansen G., Schulenburg H., Gudelj I., Beardmore R. Using a Sequential Regimen to Eliminate Bacteria at Sublethal Antibiotic Dosages 2015.
10. Imamovic L., Sommer M.O. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci. Transl. Med. 2013, 5. (204ra132-204ra132).
11. Japoni A., Alborzi A., Kalani M., Nasiri J., Hayati M., Farshad S. Susceptibility patterns and cross-resistance of antibiotics against Pseudomonas aeruginosa isolated from burn patients in the South of Iran. Burns 2006, 32:343-347.
12. Kahlmeter G., Menday P. Cross-resistance and associated resistance in 2478 Escherichia coli isolates from the Pan-European ECO SENS Project surveying the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections. J. Antimicrob. Chemother. 2003, 52:128-131.
13. Laxminarayan R., Duse A., Wattal C., Zaidi A.K., Wertheim H.F., Sumpradit N., Vlieghe E., Hara G.L., Gould I.M., Goossens H. Antibiotic resistance - the need for global solutions. Lancet Infect. Dis. 2013, 13:1057-1098.
14. Lázár V., Pal Singh G., Spohn R., Nagy I., Horváth B., Hrtyan M., Busa-Fekete R., Bogos B., Méhi O., Csörgo B. Bacterial evolution of antibiotic hypersensitivity. Mol. Syst. Biol. 2013, 9.
15. Lázár V., Nagy I., Spohn R., Csörgo B., Györkei Á., Nyerges Á., Horváth B., Vörös A., Busa-Fekete R., Hrtyan M. Genome-wide analysis captures the determinants of the antibiotic cross-resistance interaction network. Nat. Commun. 2014, 5.
16. Lewis F.I., McCormick B.J. Revealing the complexity of health determinants in resource-poor settings. Am. J. Epidemiol. 2012, (kws183).
17. Lewis F.I., Ward M.P. Improving epidemiologic data analyses through multivariate regression modelling. Emerg. Themes Epidemiol. 2013, 10:1-10.
18. Livermore D.M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin. Infect. Dis. 2002, 34:634-640.
19. Ludwig A., Berthiaume P., Boerlin P., Gow S., Léger D., Lewis F.I. Identifying associations in Escherichia coli antimicrobial resistance patterns using additive Bayesian networks. Prev. Vet. Med. 2013, 110:64-75.
20. Munck C., Gumpert H.K., Wallin A.I.N., Wang H.H., Sommer M.O. Prediction of resistance development against drug combinations by collateral responses to component drugs. Sci. Transl. Med. 2014, 6. (262ra156-262ra156).
21. Obolski U., Hadany L. Implications of stress-induced genetic variation for minimizing multidrug resistance in bacteria. BMC Med. 2012, 10:89.
22. Obolski U., Alon D., Hadany L., Stein G.Y. Resistance profiles of coagulase-negative staphylococci contaminating blood cultures predict pathogen resistance and patient mortality. J. Antimicrob. Chemother. 2014, (dku156).
23. Obolski U., Stein G.Y., Hadany L. Antibiotic restriction might facilitate the emergence of multi-drug resistance. PLoS Comput. Biol. 2015, 11.
24. Ochman H., Lawrence J.G., Groisman E.A. Lateral gene transfer and the nature of bacterial innovation. Nature 2000, 405:299-304.
25. Oz T., Guvenek A., Yildiz S., Karaboga E., Tamer Y.T., Mumcuyan N., Ozan V.B., Senturk G.H., Cokol M., Yeh P. Strength of selection pressure is an important parameter contributing to the complexity of antibiotic resistance evolution. Mol. Biol. Evol. 2014, (msu191).
26. Pál C., Papp B., Lázár V. Collateral sensitivity of antibiotic-resistant microbes. Trends Microbiol. 2015.
27. Paul M., Benuri-Silbiger I., Soares-Weiser K., Leibovici L. β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004.
28. Peralta G., Sánchez M.B., Garrido J.C., De Benito I., Cano M.E., Martínez-Martínez L., Roiz M.P. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J. Antimicrob. Chemother. 2007, 60:855-863.
29. Piddock L.J. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. Rev. 2006, 19:382-402.
30. Plummer M. JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling. Proceedings of the 3rd International Workshop on Distributed Statistical Computing 2003, 125. Technische Universit at Wien.
31. Rogers B.A., Aminzadeh Z., Hayashi Y., Paterson D.L. Country-to-country transfer of patients and the risk of multi-resistant bacterial infection. Clin. Infect. Dis. 2011, 53:49-56.
32. Sanz-García M., Fernández-Cruz A., Rodríguez-Créixems M., Cercenado E., Marin M., Muñoz P., Bouza E. Recurrent Escherichia coli bloodstream infections: epidemiology and risk factors. Medicine 2009, 88:77-82.
33. Tamma P.D., Cosgrove S.E., Maragakis L.L. Combination therapy for treatment of infections with gram-negative bacteria. Clin. Microbiol. Rev. 2012, 25:450-470.
34. Team, R.C., R Development Core Team R: A Language and Environment for Statistical Computing 2014, R Foundation for Statistical Computing, Vienna, Austria.